Increlex FDA Approval History
FDA Approved: Yes (First approved August 30, 2005)
Brand name: Increlex
Generic name: mecasermin
Dosage form: Injection
Company: Tercica, Inc.
Treatment for: Primary IGF-1 Deficiency
Increlex (mecasermin) contains human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology. Increlex is indicated for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Development timeline for Increlex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.